FDA drug approval workshop
This article was originally published in The Tan Sheet
Executive Summary
A public workshop for businesses marketing unapproved OTC and prescription drugs will be hosted by FDA Jan. 9 in Rockville, Md., the agency announces in the Nov. 1 Federal Register. FDA will provide clarification and direction to companies on how to seek drug approval, and topics slated for the meeting include NDAs, ANDAs, OTC monographs, application processes, user fees and market exclusivity. Participants must register for the meeting by Nov. 15, which is also the deadline to propose discussion topics for the workshop. FDA says it is convening the meeting because many companies sought clarification following the June 2006 publication of the agency's Marketed Unapproved Drugs-Compliance Policy Guide (1"The Tan Sheet" June 12, 2006, p. 3)...
You may also be interested in...
FDA Employs Carrot, Stick Under Unapproved Drug Enforcement Strategy
Unapproved drugs that "present direct challenges" to FDA's new drug approval and OTC drug monograph systems will be high priority for enforcement actions, according to an agency guidance released June 8
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.